Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024
Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, has announced it will report its second quarter 2024 financial results and provide a corporate update on August 8, 2024. The company is developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). A conference call and live audio webcast will be held at 4:30 p.m. ET on the same day.
Interested parties can join the call by dialing (877) 870 4263 (domestic) or (412) 317 0790 (international) and asking to join the Trevi Therapeutics call. A live audio webcast will be available on the company's website, with an archived replay accessible for 30 days following the event.
Trevi Therapeutics (Nasdaq: TRVI), un'azienda biofarmaceutica in fase clinica, ha annunciato che riporterà i suoi risultati finanziari del secondo trimestre 2024 e fornirà un aggiornamento aziendale il 8 agosto 2024. L'azienda sta sviluppando Haduvio™ (nalbuphina ER orale) per il trattamento della tosse cronica nella fibrosi polmonare idiopatica (IPF) e nella tosse cronica refrattaria (RCC). Una conferenza telefonica e un webcast audio dal vivo si terranno alle 4:30 p.m. ET nello stesso giorno.
Le parti interessate possono partecipare alla chiamata componendo il numero (877) 870 4263 (nazionale) o (412) 317 0790 (internazionale) e chiedendo di unirsi alla chiamata di Trevi Therapeutics. Un webcast audio dal vivo sarà disponibile sul sito web dell'azienda, con una registrazione archiviata accessibile per 30 giorni dopo l'evento.
Trevi Therapeutics (Nasdaq: TRVI), una compañía biofarmacéutica en etapa clínica, ha anunciado que reportará sus resultados financieros del segundo trimestre de 2024 y proporcionará una actualización corporativa el 8 de agosto de 2024. La empresa está desarrollando Haduvio™ (nalbufina ER oral) para tratar la tos crónica en la fibrosis pulmonar idiopática (FPI) y la tos crónica refractaria (TCR). Se llevará a cabo una conferencia telefónica y una transmisión en vivo de audio a las 4:30 p.m. ET el mismo día.
Las partes interesadas pueden unirse a la llamada marcando el (877) 870 4263 (nacional) o el (412) 317 0790 (internacional) y pidiendo unirse a la llamada de Trevi Therapeutics. Una transmisión en vivo de audio estará disponible en el sitio web de la empresa, con una repetición archivada accesible durante 30 días después del evento.
Trevi Therapeutics (Nasdaq: TRVI)는 임상 단계의 생명 의학 회사로, 2024년 2분기 재무 결과를 발표하고 2024년 8월 8일에 기업 업데이트를 제공할 것이라고 밝혔습니다. 이 회사는 특발성 폐섬유증(IPF) 및 난치성 만성 기침(RCC) 치료를 위해 Haduvio™(경구형 날부핀 ER)를 개발하고 있습니다. 같은 날 오후 4시 30분 ET에 전화회의와 실시간 오디오 웹캐스트가 진행될 예정입니다.
관심 있는 분들은 (877) 870 4263 (국내) 또는 (412) 317 0790 (국제)로 전화하여 Trevi Therapeutics의 전화 회의에 참가 요청을 할 수 있습니다. 회사 웹사이트에서는 라이브 오디오 웹캐스트가 제공되며, 행사 후 30일 동안 재생 가능한 보관 녹음이 가능합니다.
Trevi Therapeutics (Nasdaq: TRVI), une entreprise biopharmaceutique en phase clinique, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 et fournira une mise à jour de l'entreprise le 8 août 2024. L'entreprise développe Haduvio™ (nalbuphine ER orale) pour traiter la toux chronique dans la fibrose pulmonaire idiopathique (FPI) et la toux chronique réfractaire (TCR). Une conférence téléphonique et un webcast audio en direct auront lieu le même jour à 16h30 ET.
Les parties intéressées peuvent rejoindre l'appel en composant le (877) 870 4263 (domestique) ou le (412) 317 0790 (international) et en demandant à rejoindre l'appel de Trevi Therapeutics. Un webcast audio en direct sera disponible sur le site Web de l'entreprise, avec un replay archivé accessible pendant 30 jours après l'événement.
Trevi Therapeutics (Nasdaq: TRVI), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat angekündigt, dass es am 8. August 2024 seine finanziellen Ergebnisse für das zweite Quartal 2024 berichten und ein Unternehmensupdate bereitstellen wird. Das Unternehmen entwickelt Haduvio™ (orale Nalbufin ER) zur Behandlung von chronischem Husten bei idiopathischer Lungenfibrose (IPF) und refraktärem chronischen Husten (RCC). Am selben Tag wird um 16:30 Uhr ET eine Telefonkonferenz und ein Live-Audio-Webcast stattfinden.
Interessierte Parteien können an dem Anruf teilnehmen, indem sie (877) 870 4263 (inländisch) oder (412) 317 0790 (international) wählen und um Teilnahme an der Trevi Therapeutics-Konferenz bitten. Ein Live-Audio-Webcast wird auf der Website des Unternehmens verfügbar sein, mit einer archivierten Wiederholung, die 30 Tage nach der Veranstaltung zugänglich ist.
- Trevi Therapeutics is progressing with the development of Haduvio™ for chronic cough treatments
- The company is maintaining transparency by hosting a conference call and webcast for investors
- None.
Conference call and webcast to be held at 4:30 p.m. ET
To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is a dual ĸ-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergistic antitussive effect to treat chronic cough. Parenteral nalbuphine is not scheduled by the
The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal benefit to patients. Chronic cough affects up to
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-second-quarter-2024-financial-results-and-provide-a-corporate-update-on-august-8-2024-302212091.html
SOURCE Trevi Therapeutics, Inc.
FAQ
When will Trevi Therapeutics (TRVI) report its Q2 2024 financial results?
What time is Trevi Therapeutics' (TRVI) Q2 2024 earnings call scheduled for?
What treatments is Trevi Therapeutics (TRVI) currently developing?
How can investors join Trevi Therapeutics' (TRVI) Q2 2024 earnings call?
